

The price for exercising warrants of series TO 4 to subscribe for new shares has been set to SEK 5.96 per new share

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE MEASURES OTHER THAN THOSE REQUIRED UNDER SWEDISH LAW. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Prostatype Genomics AB ("Prostatype" or "the Company") hereby announces that the exercise price for the warrants of series TO 4 ("TO 4"), which were issued in connection with the rights issue of units carried out by the Company earlier during 2024, has been set. The subscription price is set at 5.96 SEK, corresponding to 70 percent of the volume-weighted average price of the Company's share during the period 11 – 22 November 2024. Terms for exercising warrants of series TO 4 are, after adjustment following the reverse split of Prostatype's share on October 31, that one thousand (1,000) warrants of series TO 4 grant the holder the right to subscribe for one (1) new share in Prostatype. The exercise period commences on 25 November 2024 and runs to and including 9 December 2024

In August 2024, Prostatype carried out a rights issue which provided the Company with approximately SEK 35.7 million before issue costs. Through the rights issue and subsequent directed issue to guarantors, a total of 1,663,016,092 warrants of series TO 4 were issued. Terms for exercising warrants, after adjustment due to the Company's reverse share split on October 31, 2024, are that a thousand (1,000) warrants of series TO 4 grant the right to subscribe for one (1) new share in Prostatype during the exercise period, which runs from 25 November 2024 to 9 December 2024. The subscription price for TO 4 has been set at 5.96 SEK per share, corresponding to 70 percent of the volume-weighted average price of the Company's share during the period 11 November to 22 November 2024. If all warrants of series TO 4 are exercised, the Company will receive approximately 9.9 million SEK before issue related costs.

If all TO 4 are exercised for subscription, the number of shares in Prostatype will increase by 1,663,016 shares to a total of 6,811,367 shares and the share capital will increase by SEK 166,301.60 to SEK 681,136.70. The dilution if all warrants are exercised amounts to approximately 24.4 percent to the capital and number of votes.

Complete terms and instructions for warrants of series TO 4 are available on the Company's website (www.prostatypegenomics.com). An information folder containing summary information about the warrant exercise will also be available on Prostatype Genomics' (www.prostatypegenomics.com) and Nordic Issuing AB's (www.nordic-issuing.se) respective websites in connection with the initiation of the exercise period.

Important dates

- 25 November 2024: Exercise period commences
- 5 December 2024: Last day of trading in TO 4
- 9 December 2024: Exercise period ends
- 10 December 2024: Preliminary date for publication of outcome of the exercise
- 20 December 2024: Preliminary date for conversion from interim shares

Advisors

In connection with the warrant exercise, Prostatype has engaged Gemstone Capital A/S as financial advisor, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as issuing agent.

For more information, please contact:

Fredrik Rickman, VD

Tel: +46 (0)73-049 77 01

E-mail: fredrik.rickman@prostatypegenomics.com

About Prostatype

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Important Information

This press release does not constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, unit rights, BTUs, or other securities in Prostatype Genomics AB. Investors should not subscribe for or acquire any securities other than on the basis of the information in the prospectus published prior to the commencement of the subscription period in the Rights Issue. No action has been or will be taken to allow a public offering in any jurisdictions other than Sweden.

This press release may not be released, published, or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, the United Kingdom, South Africa, South Korea, Russia, Belarus, or any other jurisdiction where the distribution of this press release would be unlawful. This press release does not constitute an offer to sell new shares, warrants, subscription rights, BTUs, or other securities to any person in a jurisdiction where such an offer would be unlawful or would require prospectuses, additional registration, or other measures beyond those required by Swedish law. The prospectus and other documents related to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires actions as mentioned above or where it would conflict with the regulations of such country. Any actions in violation of these instructions may constitute a breach of applicable securities laws.

No shares, warrants, unit rights, BTUs, or other securities have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered, subscribed for, exercised, pledged, sold, resold, allotted, delivered, or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United States.

This press release may contain certain forward-looking statements reflecting the Company's current views on future events as well as financial and operational developments. Words such as "intends," "assesses," "expects," "may," "plans," "believes," "estimates," and other expressions indicating or predicting future developments or trends and that are not based on historical facts constitute forward-looking statements. Forward-looking statements are, by nature, associated with both known and unknown risks and uncertainties, as they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments, and actual outcomes may differ materially from what is expressed in the forward-looking statements. Neither the Company nor any other party undertakes to review, update, confirm, or publicly announce any revisions of any forward-looking statements to reflect events that occur or circumstances that arise with regard to the content of this press release, unless required by law or the Nasdaq First North Growth Market's regulations.